m6A-centered Crosstalk Information

Mechanism of Crosstalk between m6A Modification and Epigenetic Regulation
Crosstalk ID
M6ACROT05679
 [1]
m6A modification NEAT1 NEAT1 VIRMA Methylation : m6A sites Direct Enhancement Non-coding RNA NEAT1 Regulated Target  lncRNA       miRNA   circRNA
m6A Modification:
m6A Regulator Protein virilizer homolog (VIRMA) WRITER
 Regulator Info 
m6A Target Nuclear paraspeckle assembly transcript 1 (NEAT1)
 Targert Gene 
Epigenetic Regulation that have Cross-talk with This m6A Modification:
Epigenetic Regulation Type Non-coding RNA (ncRNA)
Epigenetic Regulator Nuclear paraspeckle assembly transcript 1 (NEAT1) LncRNA View Details
Crosstalk Relationship m6A  →  ncRNA Enhancement
Crosstalk Mechanism m6A regulators directly modulate the functionality of ncRNAs through specific targeting ncRNA
Crosstalk Summary Mechanistically, we reveal that VIRMA overexpression upregulates the m6A-modified long non-coding RNA, Nuclear paraspeckle assembly transcript 1 (NEAT1), which contributes to breast cancer cell growth.
Responsed Disease Breast cancer ICD-11: 2C60
 Disease Info 
In-vitro Model
 SK-BR-3 Breast adenocarcinoma Homo sapiens CVCL_0033
MDA-MB-231 Breast adenocarcinoma Homo sapiens CVCL_0062
MDA-MB-453 Breast adenocarcinoma Homo sapiens CVCL_0418
MCF-7 Invasive breast carcinoma Homo sapiens CVCL_0031
AU565 Breast adenocarcinoma Homo sapiens CVCL_1074
Hs 578T Invasive breast carcinoma Homo sapiens CVCL_0332
HEK293T Normal Homo sapiens CVCL_0063
In-vivo Model Mice were acclimatised at the Centenary Institute Animal Facility for a minimum of 7 days after initial arrival. Prior to tumour injection, mice were anaesthetised by ketamine/xylazine by intraperitoneal injection. Subsequently, the fur surrounding the 4th mammary fat pad on the right was removed using the hair removal cream. MDA-MB-231 cells (5 × 106) in 100 L of 1:1 HBSS:Matrigel were then injected subcutaneously into the 4th right mammary fat pad using 27 g insulin needles. Mice were injected intraperitoneally with the reversal atipamezole to improve the recovery from anaesthesia. Mice were monitored twice weekly by assessing body condition, measuring body weights and tumour sizes. The frequency of monitoring was increased to daily when tumours reached > 500 mm3 in size. Mice were killed when tumours reached > 1000 mm3 in size and the relevant organs were harvested for analysis.
Full List of Potential Compound(s) Related to This m6A-centered Crosstalk
2C60: Breast cancer 2 Compound(s) Regulating the Disease Click to Show/Hide the Full List
 Compound Name Entrectinib Approved [2]
Synonyms
1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK
    Click to Show/Hide
External Link
CID: 25141092
TTD: D0O0LS
DrugBank: DB11986
 Compound Name Everolimus Approved [3]
External Link
CID: 6442177
TTD: D09ZSC
DrugBank: DB01590
References
Ref 1 Overexpression of VIRMA confers vulnerability to breast cancers via the m(6)A-dependent regulation of unfolded protein response. Cell Mol Life Sci. 2023 May 19;80(6):157. doi: 10.1007/s00018-023-04799-4.
Ref 2 Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372... Cancer Discov. 2017 Apr;7(4):400-409.
Ref 3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015